A hand-drawn lab notebook / BPC-157 + TB-500
BPC-157 TB-500 is a two-peptide research blend paired for complementary tissue-repair mechanisms.
Two synthetic peptides drawn onto one page: BPC-157's cytoprotective, pro-angiogenic signal beside TB-500's actin-binding migration signal. We log what each component study measured — and circle, in red, the one fact that holds the whole story together: no controlled combination trial exists.
Two peptides, sketched onto one page
BPC-157 TB-500 is a research-community pairing of two distinct synthetic peptides, marketed and discussed under the nickname "Wolverine." It is not a single chemical entity. It has no single molecular weight, no shared CAS number, and no approved therapeutic indication anywhere. What it has are two well-defined components and a hypothesis about why they belong together.
The first component is BPC-157 — Body Protection Compound 157 — a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. In preclinical models it acts as a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2]. The second is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889 Da) corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4. Its helix binds monomeric G-actin in a 1:1 complex, regulating the cytoskeletal dynamics that drive cell migration [3].
The rationale for pairing them is mechanistic complement: a vascular-and-cytoprotection signal beside a cell-migration signal, converging on a tissue-repair node. That rationale is the drawn hypothesis on the page. The experiment that would test it has never been run. This site treats the components honestly — citing every quantitative claim to its source study — and keeps the combination's missing evidence visible rather than filled in. For the pharmacokinetic picture, see BPC-157 TB-500 dosage and pharmacokinetics; for the mechanisms, see BPC-157 and TB-500 mechanisms.
What Is the Wolverine peptide blend?
The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, sold and discussed as a tissue-repair "stack." The name is branding, not chemistry. There is no "Wolverine molecule" — there are two peptides in one vial, often labeled with a combined per-vial mass such as 10 mg BPC-157 plus 10 mg TB-500.
The term carries a search problem worth naming: most online volume for "wolverine peptide" is conflated with the fictional character, not the compound. The clean compound-intent term is the pairing itself, BPC-157 TB-500.
The Wolverine stack: BPC-157 and TB-500 combined
The BPC-157 TB-500 stack pairs two peptides chosen for non-overlapping mechanisms. BPC-157 supplies the local angiogenic and cytoprotective leg — in transected rat Achilles tendon it improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in vitro it reversed growth inhibition of tendocytes into stimulation [1]. TB-500 supplies the cytoskeletal leg, through the 1:1 G-actin sequestration its parent protein Thymosin Beta-4 was crystallographically shown to perform [3].
The word "stack" implies the combination has been worked out. It has not. A 2025 systematic review of BPC-157 in orthopaedic sports medicine examined 36 studies — 35 preclinical, only one human — found no clinical safety data, and made no mention of TB-500 or any combination [9]. The stack is two separately characterized peptides; the assembled product has never been tested as a unit. See why researchers pair the two peptides for the full mechanistic rationale.
What this notebook is — and is not
This is an independent editorial digest of the published research on the BPC-157 TB-500 blend and its two components. It is a reading record, not a clinic, not a pharmacy, and not a vendor. "Chemical" in the name reads as the lab-bench register — a working notebook — not a storefront.
We state findings as they appear in the literature: a dose studied in a species by a route, an effect measured against a control, a mechanism resolved by a structure. Where the evidence is preclinical, we say so. Where it is single-compound rather than combination, we say so. And where it is absent — as it is for the blend's human efficacy and combination safety — we leave the entry blank rather than fill it in. The regulatory picture, including the FDA's current 503A category for both components, lives on Wolverine legal status and FDA 503A category.